BMYMP News and Press, Bristol-Myers Squibb $2Pr From 02/13/24

2024-02-13 00:39:21 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

2024-02-02 12:43:08 ET Bristol-Myer Squibb Company (BMY) Q4 2023 Earnings Conference Call February 2, 2024 08:00 AM ET Company Participants Tim Power - VP, IR Chris Boerner - CEO David Elkins - EVP & CFO Sarnit Hirawat - Chief Medical Officer Adam Len...

2024-01-26 11:03:16 ET More on Bristol-Myers Squibb Company PFD CONV 2 Bristol-Myers Squibb Company (BMY) J.P. Morgan 42nd Annual Healthcare Conference (Transcript) Bristol-Myers Squibb Company (BMY) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) ...

2024-01-21 02:50:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended December 31, 2023, Baron Health Care Fund® (the Fund) advanc...

2024-01-20 00:49:32 ET Summary In 2015, I started publishing updates regarding my dividend growth portfolio, and I keep doing so every quarter. This is part of being transparent with my readers, so they can see what I hold and its correlation with my writing. This article summ...

2024-01-19 08:00:00 ET Summary The healthcare sector is overvalued by 12.5% based on 11-year averages. Nevertheless, the healthcare providers industry shows a good value score. iShares U.S. Healthcare ETF is an unattractive alternative to XLV. We look at 10 healthcare stocks c...

2024-01-12 13:46:01 ET Summary Pfizer Inc. stock has been on a protracted, yearlong decline due to stronger-than-expected normalization in COVID product uptake rates in 2023. But management's conservative 2024 guidance for COVID product revenues sufficiently de-risks for related h...

2024-01-12 10:12:55 ET Summary I discuss a cheap Big Pharma stock and its performance in the market. I provide an overview of the stock's history, including its R&D cycle, dividend and yield on cost history, and valuation. With Eliquis generating $11.78 Billion in revenue ...

2024-01-10 13:17:03 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

2024-01-10 08:01:12 ET Summary Data readout from phase 2 GALAXIES Lung-201 study, using belrestotug in combination with dostarlimab to treat patients with 1st-line advanced/metastatic NSCLC, expected 2024. The global non-small cell lung cancer market is expected to reach $36.9 bil...